Ann: Positive DEP Cabazitaxel Phase 2 Results in Multiple Cancer, page-74

If Sanofi don’t licence DEP-Cabazitaxel and DEP-Docetaxel, and Pfizer don’t licence DEP-Irinotecan, and it appears neither want them after years of confidential sharing of data by Starpharma, IMO there’s next to zero chance of a 3rd party licencing any of the three.

Starpharma do not have the funds and will not be able to raise the large funds (on reasonable terms) required to conduct a single Phase 3 trial themselves. So where does that leave Starpharma?

P.S. To be fair they could theoretically raise $100m for a single modest Phase 3 trial, but I would guesstimate SPL would have to issue 1.2 billion shares at 8 cents each to raise that amount.